CA-C3.AI
25.2.2021 15:02:10 CET | Business Wire | Press release
C3 AI today announced that it was awarded a broad-ranging omnibus patent for the company’s end-to-end enterprise AI solution, C3 AI® Suite, further solidifying the company’s position as a leading enterprise AI software provider for accelerating digital transformation, as well as strengthening C3 AI’s intellectual property and competitive advantage.
The newly issued U.S. patent (No.10,817,530) was granted for “systems, methods, and devices for an enterprise AI application development platform.” The patent encompasses not only advanced data processing and AI application development, but also the extensive array of techniques necessary to build an end-to-end enterprise AI platform, including C3 AI’s unique model-driven architecture.
“This patent is the most significant and substantial we have been awarded to date,” said Thomas M. Siebel, CEO of C3 AI. "When we filed years ago, no one else conceived of a comprehensive, end-to-end solution with a model-driven architecture that accelerates the delivery and reduces the complexity of developing and operating enterprise AI applications. This sweeping patent further extends our leadership and maturity in this market as well as our commitment to protect our IP and our customers, ensuring their ability to rapidly deploy and scale AI with confidence to drive high-value outcomes across their business."
The comprehensive patent protects many methods and techniques that enable the development of enterprise AI applications, including:
- Use of a model-driven architecture for the “design, development, deployment, and operation of next-generation cyber-physical software applications and business processes”
- The “application of advanced data aggregation methods, data persistence methods, data analytics, and machine learning methods”
- Methods for “implementing abstraction and continuous processing of the aggregated data using a model-driven architecture”
- Embedding capabilities “in a model-driven architecture type system to recommend actions based on real-time analysis of petabyte-scale data sets and telemetry data from millions to billions of endpoints”
- The use of an ontology, or canonical data mode, that “comprises conceptual domain models of various attributes and processes related to different entities or domains,” wherein “the various attributes and processes comprise persistence, data representations, data interrelationships, computing processes, or machine learning algorithms” and “is extensible to allow users of said application development platform to integrate new data formats”
- A standardized data format that “comprises an aggregation and correlation of two or more data formats associated with the plurality of data stores, while ensuring automatic and guaranteed referential integrity of the underlying two or more data formats,” wherein “the standardized data format is automatically exposed and accessible through RESTful interfaces”
- “A method comprising: storing time-series data in a key-value store and non-time-series data in a relational database; implementing, on an application development platform, abstraction over a plurality of data stores comprising the key-value store and the relational database, wherein the abstraction comprises a metadata-based mapping framework over a plurality of data formats associated with the plurality of data stores.”
“This appears to be a seminal patent,” said Bruce Sewell, a C3 AI director, and former general counsel of Apple and Intel. “A close reading reveals a number of fundamental concepts that appear both necessary and sufficient to deploy an enterprise AI application.”
C3 AI has invested over a decade building a leading platform that brings enterprise AI solutions across industries at global, industrial scale to drive digital transformation. The C3 AI Suite is a scalable, production-ready enterprise AI solution that enables organizations to rapidly design, develop, and deploy enterprise-scale AI applications on any public, private, or hybrid cloud environment. It allows organizations to integrate and unify massive, fragmented data sets from disparate enterprise and extraprise data stores and sensors, and apply machine learning algorithms to generate predictive insights that improve efficiency, reduce costs, increase revenue, enhance safety, and drive greater profitability.
At the core of the C3 AI Suite is an open, model-driven architecture that significantly simplifies and accelerates data science and the development of enterprise AI applications – from data integration and data management to model development, validation, and deployment. With C3 AI’s model-driven architecture, a small team of developers can build and deploy enterprise-class AI applications in a matter of weeks, with up to 99 percent less code compared to other methods, by using conceptual models of all the elements an application requires.
C3 AI is establishing a Technology Licensing Office to enable third parties to license C3 AI-patented technologies for use in their own products and solutions.
This new patent follows the issue of a patent awarded for advanced methods of data processing. C3 AI holds additional patents in the areas of cybersecurity, fraud detection, and energy data processing.
Patent details are available in the United States Trademark and Patent Office database .
About C3.ai, Inc.
C3.ai, Inc. (NYSE: AI) is a leading provider of enterprise AI software for accelerating digital transformation. C3 AI delivers a family of fully integrated products: C3 AI® Suite, an end-to-end platform for developing, deploying, and operating large-scale AI applications; C3 AI Applications, a portfolio of industry-specific SaaS AI applications; C3 AI CRM, a suite of industry-specific CRM applications designed for AI and machine learning; and C3 AI Ex Machina, a no-code AI solution to apply data science to everyday business problems. The core of the C3 AI offering is an open, model-driven AI architecture that dramatically simplifies data science and application development. Learn more at: www.c3.ai
View source version on businesswire.com: https://www.businesswire.com/news/home/20210225005304/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
Galderma Tackles Menopause-related Skin Changes With Global Survey and Clinical Trial Inclusivity30.1.2026 07:00:00 CET | Press release
Results from a global survey of over 4,300 women across five continents presented at IMCAS 2026 reveal a knowledge gap on the impact of menopause on the skin, despite women experiencing around three skin changes during menopause1 Galderma will also host a symposium delving into the challenges and science behind menopause-related skin changes and aesthetic solutions at the congress Galderma is committed to raising awareness of the impact of menopause on the skin, fostering meaningful dialogue between patients and healthcare professionals, and advancing science-backed solutions by incorporating menopausal status into all injectable aesthetics clinical trials Galderma (SIX: GALD) has unveiled findings from a global survey of peri- and post-menopausal women from nine countries exploring the impact of menopause on the skin at the International Master Course on Aging Science (IMCAS) 2026 World Congress in Paris, France, from January 29-31, 2026. The survey found that over 50% of women learne
Andersen Consulting styrker sine cybersikkerhedskompetencer med tilføjelsen af RedLegg30.1.2026 00:18:00 CET | Pressemeddelelse
Andersen Consulting styrker sit cybersikkerhedsudbud gennem en samarbejdsaftale med RedLegg, der er et cybersikkerhedsfirma med speciale i administreret trusselsdetektion og rådgivningsydelser. RedLegg blev grundlagt i 2008 og har hovedsæde i USA. RedLegg tilbyder skræddersyede cybersikkerhedsløsninger med fokus på risikominimering, administrerede sikkerhedstjenester og penetrationstest. Virksomhedens ydelser omfatter blandt andet managed detection and response (MDR), hændelsesrespons, udvikling af sikkerhedspolitikker samt virtuel CISO-rådgivning. RedLegg betjener mellemstore virksomheder inden for finans, forsikring, jura og sundhedssektoren og kombinerer automatisering, trusselsintelligens og et dedikeret Security Operations Center (SOC) for at hjælpe organisationer med at effektivisere deres cybersikkerhedsoperationer og opbygge langsigtet modstandsdygtighed. "Vores fokus har altid været at hjælpe kunder med at skære støjen fra og prioritere det, der virkelig betyder noget – nemlig
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
